Zacks: Biolase, Inc. (BIOL) Given Average Rating of “Strong Buy” by Analysts
Biolase, Inc. (NASDAQ:BIOL) has been assigned an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.
Analysts have set a 12 month consensus price target of $2.50 for the company, according to Zacks. Zacks has also given Biolase an industry rank of 107 out of 265 based on the ratings given to related companies.
Separately, ValuEngine raised Biolase from a “sell” rating to a “hold” rating in a report on Monday, October 2nd.
ILLEGAL ACTIVITY WARNING: “Zacks: Biolase, Inc. (BIOL) Given Average Rating of “Strong Buy” by Analysts” was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/12/02/zacks-biolase-inc-biol-given-average-rating-of-strong-buy-by-analysts.html.
Biolase Company Profile
BIOLASE, Inc (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Biolase Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biolase Inc. and related companies with MarketBeat.com's FREE daily email newsletter.